Mechanistically, dual inhibition of HDAC6 and CYP17A1 by cp8 disrupted redox homeostasis and stemness-associated pathways, leading to altered ROS metabolism, reduced MGMT expression, and attenuation of GSC-driven tumor growth while restoring FLG-mediated tumor suppression.<h4>Conclusion</h4>This study establishes FLG as a novel therapeutic target in GBM and validates the suppressive efficacy of cp8 on the characteristics of TMZ resistance, highlighting the translational potential as a multitargeted therapy against TMZ-resistant GBM. The gene discussed is HDAC6; the disease is neoplasm.